NCT00521742View on ClinicalTrials.gov

Efficacy of Pioglitazone Compared to Glyburide in Treating Subjects With Type 2 Diabetes Mellitus and Mild Cardiac Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

March 31, 2001

Primary Completion Date

January 31, 2003

Study Completion Date

January 31, 2003

Conditions
Diabetes Mellitus
Interventions
DRUG

Pioglitazone

Pioglitazone 15 mg to 45 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally, once daily for up to 52 weeks.

DRUG

Glyburide

Glyburide 2.5 mg to 15 mg, capsules, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 52 weeks.

DRUG

Pioglitazone

Pioglitazone 15 mg or 30 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally once daily for up to 52 weeks.

DRUG

Glyburide

Glyburide 5 mg or 10 mg, capsules, orally, once daily and pioglitazone placebo-matching tablets, orally once daily for up to 52 weeks.

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
collaborator

Takeda Pharmaceuticals North America, Inc.

INDUSTRY

lead

Takeda

INDUSTRY